{"hands_on_practices": [{"introduction": "Accurately classifying Juvenile Idiopathic Arthritis (JIA) is the foundational step in determining prognosis and guiding therapy. The International League of Associations for Rheumatology (ILAR) criteria are not a simple checklist but a hierarchical system of inclusion and exclusion rules. This practice challenges you to apply this complex logic to a clinically nuanced case, a crucial skill for any pediatric specialist [@problem_id:5165155].", "problem": "A child aged $8$ years presents with $6$ months of asymmetric arthritis affecting the right knee, left knee, and right ankle. The child is afebrile, has no hepatosplenomegaly, and no serositis. There is no dactylitis, enthesitis, or inflammatory back pain. Ophthalmology confirms chronic anterior uveitis. Rheumatoid factor (RF) is negative on one measurement; antinuclear antibodies (ANA) are positive. Human leukocyte antigen B27 (HLA-B27) is negative. A dermatologist has diagnosed well-demarcated erythematous plaques with silvery scale over the scalp as psoriasis. There is no nail pitting or onycholysis. There is no personal or first-degree family history of inflammatory bowel disease, ankylosing spondylitis, reactive arthritis, or psoriasis. The child is female, and at baseline has involvement of $3$ joints.\n\nUsing the International League of Associations for Rheumatology (ILAR) classification system for juvenile idiopathic arthritis (JIA), and starting from core definitions and exclusion principles, determine the most appropriate JIA category for this child and justify whether the scalp psoriasis without nail changes supports inclusion in that category or necessitates exclusion.\n\nWhich option best states the ILAR classification and the key justification?\n\nA. Psoriatic JIA: Physician-diagnosed psoriasis of the scalp fulfills the major criterion for the psoriatic category; absence of nail changes is not required, and no ILAR exclusions apply in this case.\n\nB. Undifferentiated JIA: The absence of nail changes and dactylitis precludes the psoriatic category unless there is a first-degree relative with psoriasis; therefore, with only scalp involvement, classification defaults to undifferentiated.\n\nC. Oligoarticular JIA: Involvement of fewer than $5$ joints during the first $6$ months mandates oligoarticular classification; limited, scalp-only psoriasis is insufficient evidence and is an exclusion for psoriatic JIA.\n\nD. Enthesitis-related arthritis (ERA): Onset after age $6$ years favors ERA; HLA-B$27$ status is not decisive, and uveitis argues against psoriatic JIA, so the child should be classified as ERA.", "solution": "The problem statement is first subjected to validation.\n\n### Step 1: Extract Givens\n-   **Patient Age:** $8$ years\n-   **Disease Duration:** $6$ months\n-   **Arthritis:** Asymmetric, affecting $3$ joints (right knee, left knee, right ankle).\n-   **Systemic Symptoms:** Afebrile, no hepatosplenomegaly, no serositis.\n-   **Musculoskeletal Features:** No dactylitis, no enthesitis, no inflammatory back pain.\n-   **Ophthalmology:** Chronic anterior uveitis.\n-   **Serology:** Rheumatoid factor (RF) negative (one measurement), Antinuclear antibodies (ANA) positive.\n-   **Genetics:** Human leukocyte antigen B$27$ (HLA-B$27$) negative.\n-   **Dermatology:** Physician-diagnosed psoriasis (well-demarcated erythematous plaques with silvery scale over the scalp). No nail pitting or onycholysis.\n-   **Family History:** No first-degree family history of inflammatory bowel disease, ankylosing spondylitis, reactive arthritis, or psoriasis.\n-   **Sex:** Female.\n-   **Task:** Apply the International League of Associations for Rheumatology (ILAR) classification system for juvenile idiopathic arthritis (JIA) to determine the most appropriate category and justify the significance of the scalp psoriasis.\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientifically Grounded:** The problem is based on a real-world clinical scenario and uses a standard, internationally recognized medical classification system (ILAR for JIA). All symptoms, signs, and laboratory findings are medically established concepts. The problem is scientifically sound.\n2.  **Well-Posed:** The problem provides sufficient, specific data to apply the ILAR classification rules. The question asks for a single, most appropriate classification based on these rules, which is a solvable task.\n3.  **Objective:** The description of the patient's condition is clinical and factual, using standard medical terminology. There are no subjective or opinion-based statements.\n4.  **Complete and Consistent:** The data provided are comprehensive for the purpose of JIA classification, including joint count, duration, associated features, serology, and family history. There are no internal contradictions. For instance, the joint count ($3$) is consistent with the listed joints.\n5.  **Unrealistic or Infeasible:** The clinical presentation is a plausible, albeit complex, case that could be encountered in a pediatric rheumatology practice.\n6.  **Other Flaws:** The problem is not trivial, as it requires detailed knowledge of the ILAR criteria, particularly the inclusion and exclusion rules for different categories. It is not metaphorical, ill-posed, or outside scientific verifiability.\n\n### Step 3: Verdict and Action\nThe problem statement is valid. A rigorous solution can be derived by applying the ILAR classification principles.\n\n### Solution Derivation\n\nThe analysis will proceed by systematically applying the ILAR classification criteria for JIA.\n\n**Initial Criteria for JIA:**\nThe patient is $8$ years old (onset $< 16$ years), with arthritis that has persisted for $6$ months (duration $> 6$ weeks). The cause is idiopathic. Therefore, the patient meets the general criteria for a diagnosis of JIA. We must now determine the specific category.\n\n**Evaluation of JIA Categories:**\n\n1.  **Systemic JIA:** Requires arthritis with or preceded by fever of at least $2$ weeks' duration, documented to be quotidian for at least $3$ days, and accompanied by one or more of the following: evanescent rash, generalized lymphadenopathy, hepatosplenomegaly, or serositis.\n    *   The patient is afebrile and has no hepatosplenomegaly or serositis.\n    *   **Conclusion:** Systemic JIA is excluded.\n\n2.  **Oligoarticular JIA:** Defined as arthritis affecting $1$ to $4$ joints during the first $6$ months of the disease.\n    *   The patient has arthritis in $3$ joints, which fits this numerical criterion.\n    *   However, the ILAR criteria specify **exclusions** for this category. One of a key exclusion criterion is the presence of psoriasis in the patient or a first-degree relative.\n    *   The patient has a physician-diagnosed psoriasis.\n    *   **Conclusion:** Due to the presence of psoriasis, Oligoarticular JIA is excluded, despite the joint count being $\\le 4$.\n\n3.  **Polyarticular JIA (RF-negative and RF-positive):** Defined as arthritis affecting $\\ge 5$ joints during the first $6$ months of the disease.\n    *   The patient has arthritis in only $3$ joints.\n    *   **Conclusion:** Both categories of Polyarticular JIA are excluded.\n\n4.  **Enthesitis-Related Arthritis (ERA):** Requires either (a) arthritis and enthesitis, or (b) arthritis or enthesitis with at least two of the following: sacroiliac tenderness/inflammatory back pain, HLA-B$27$ positivity, onset in a male after age $6$ years, acute anterior uveitis, or a first-degree relative with an HLA-B$27$-associated disease.\n    *   The patient has arthritis but explicitly has **no enthesitis** and **no inflammatory back pain**.\n    *   The patient is HLA-B$27$ negative and female.\n    *   The patient has *chronic* anterior uveitis, not the acute anterior uveitis characteristic of ERA.\n    *   There is no relevant family history.\n    *   **Conclusion:** The criteria for ERA are not met.\n\n5.  **Psoriatic JIA (PsA):** Requires arthritis and either:\n    *   (a) A typical psoriatic rash diagnosed by a physician.\n    *   OR\n    *   (b) At least two of the following: dactylitis, nail pitting/onycholysis, or a first-degree relative with psoriasis.\n    *   The patient has arthritis. The patient also has \"well-demarcated erythematous plaques with silvery scale over the scalp\" diagnosed by a dermatologist as psoriasis. This fulfills criterion (a).\n    *   The absence of dactylitis, nail changes, and family history is irrelevant because criterion (a) is met. The other criteria in (b) are alternatives, not requirements, if the patient has psoriasis.\n    *   We must also check the **exclusions** for PsA. These include: presence of systemic JIA, positive RF on two occasions, arthritis in an HLA-B$27$ positive male with onset after age $6$ years, or a first-degree relative with an HLA-B$27$-associated disease. None of these exclusions apply to this patient.\n    *   **Conclusion:** The patient fulfills the inclusion criteria for Psoriatic JIA and meets none of the exclusion criteria.\n\n6.  **Undifferentiated JIA:** This category applies to patients whose arthritis either (a) does not meet criteria for any category, or (b) meets criteria for two or more categories.\n    *   The patient clearly meets the criteria for one category (Psoriatic JIA) and is explicitly excluded from the others for which she might have been a candidate (e.g., Oligoarticular JIA).\n    *   **Conclusion:** Undifferentiated JIA is not the correct classification.\n\n**Summary of Derivation:** The most appropriate classification is Psoriatic JIA. The presence of a physician-diagnosed psoriatic rash is a primary inclusion criterion for this category. It also serves as an exclusion criterion for the oligoarticular category, demonstrating the hierarchical and mutually exclusive nature of the ILAR system.\n\n### Option-by-Option Analysis\n\n**A. Psoriatic JIA: Physician-diagnosed psoriasis of the scalp fulfills the major criterion for the psoriatic category; absence of nail changes is not required, and no ILAR exclusions apply in this case.**\n*   This option correctly identifies the classification as Psoriatic JIA. The justification is precise and accurate. The ILAR criteria for PsA are met by having arthritis plus a physician-diagnosed psoriatic rash, regardless of location (scalp is sufficient). The absence of nail changes is not an excluding factor, as it's part of an alternative set of criteria. The statement that no ILAR exclusions apply is also correct.\n*   **Verdict: Correct.**\n\n**B. Undifferentiated JIA: The absence of nail changes and dactylitis precludes the psoriatic category unless there is a first-degree relative with psoriasis; therefore, with only scalp involvement, classification defaults to undifferentiated.**\n*   This option is incorrect. It misinterprets the ILAR criteria for PsA. Arthritis plus a psoriatic rash is sufficient on its own. The triad of dactylitis, nail changes, and family history is an *alternative* pathway to classification if the patient does not have a psoriatic rash themselves. Since this patient has the rash, this alternative pathway is irrelevant. The classification does not default to undifferentiated.\n*   **Verdict: Incorrect.**\n\n**C. Oligoarticular JIA: Involvement of fewer than $5$ joints during the first $6$ months mandates oligoarticular classification; limited, scalp-only psoriasis is insufficient evidence and is an exclusion for psoriatic JIA.**\n*   This option is incorrect for multiple reasons. First, while the joint count fits the oligoarticular definition, the presence of psoriasis is a specific *exclusion* criterion for Oligoarticular JIA. Therefore, the classification is not \"mandated.\" Second, the statement that scalp-only psoriasis is \"insufficient evidence\" for PsA is false; any physician-diagnosed psoriasis suffices. The statement that it is an \"exclusion for psoriatic JIA\" is the opposite of the truth; it is a primary inclusion criterion.\n*   **Verdict: Incorrect.**\n\n**D. Enthesitis-related arthritis (ERA): Onset after age $6$ years favors ERA; HLA-B$27$ status is not decisive, and uveitis argues against psoriatic JIA, so the child should be classified as ERA.**\n*   This option is incorrect. The patient does not meet the core criteria for ERA, lacking enthesitis, inflammatory back pain, HLA-B$27$, and the characteristic acute uveitis. The patient's *chronic* anterior uveitis is, in fact, characteristic of Psoriatic and Oligoarticular JIA, not ERA. Therefore, the uveitis argues *for* a diagnosis like PsA, not against it.\n*   **Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "5165155"}, {"introduction": "Beyond initial classification, vigilant management of JIA involves recognizing and acting on potentially life-threatening complications. Macrophage Activation Syndrome (MAS), a form of secondary hemophagocytic lymphohistiocytosis, is a feared complication of systemic JIA requiring rapid diagnosis. This exercise provides critical practice in applying the standardized 2016 EULAR/ACR/PRINTO classification criteria to laboratory data to make a timely and accurate diagnosis [@problem_id:5165130].", "problem": "An $8$-year-old child with known systemic juvenile idiopathic arthritis (sJIA) presents with persistent fever, new hepatosplenomegaly, and laboratory abnormalities: serum ferritin $=3000$ $\\mathrm{ng/mL}$, platelet count $=120{,}000/\\mu \\mathrm{L}$, aspartate aminotransferase (AST) $=80$ $\\mathrm{U/L}$, and fibrinogen $=1.2$ $\\mathrm{g/L}$. Using established classification criteria for macrophage activation syndrome (MAS) in the context of sJIA, determine whether the patient meets criteria for MAS, carefully justifying any unit conversions and threshold comparisons required by the criteria.\n\nWhich one statement is the best conclusion based on the provided data?\n\nA. The patient meets MAS classification criteria without needing any additional laboratory values.\n\nB. The patient does not meet MAS classification criteria because the fibrinogen is not low after proper unit conversion.\n\nC. The patient does not meet MAS classification criteria because the ferritin is below the required threshold for classification in sJIA.\n\nD. The patient meets MAS classification criteria only if fasting triglycerides are elevated; without triglycerides, MAS cannot be classified.\n\nE. The patient does not meet MAS classification criteria because the platelet count must be $\\leq 100{,}000/\\mu \\mathrm{L}$ to qualify.", "solution": "The problem requires the application of established classification criteria for macrophage activation syndrome (MAS) in a patient with systemic juvenile idiopathic arthritis (sJIA). The most current and widely accepted criteria are the $2016$ European League Against Rheumatism (EULAR) / American College of Rheumatology (ACR) / Paediatric Rheumatology International Trials Organisation (PRINTO) classification criteria for MAS in sJIA.\n\nFirst, the\nproblem statement is validated.\n\n**Step 1: Extract Givens**\n- Patient Age: $8$ years old\n- Known Condition: Systemic juvenile idiopathic arthritis (sJIA)\n- Clinical Presentation: Persistent fever, new hepatosplenomegaly\n- Laboratory Data:\n    - Serum ferritin = $3000 \\, \\text{ng/mL}$\n    - Platelet count = $120,000/\\mu\\text{L}$\n    - Aspartate aminotransferase (AST) = $80 \\, \\text{U/L}$\n    - Fibrinogen = $1.2 \\, \\text{g/L}$\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, presenting a realistic clinical scenario in pediatric rheumatology. The task is to apply \"established classification criteria,\" which refers to the formal 2016 EULAR/ACR/PRINTO criteria. The provided data are sufficient to apply these criteria. The problem is well-posed, objective, and contains no scientific or logical flaws. The problem is therefore valid.\n\n**Step 3: Verdict and Action**\nThe problem is valid. The solution will proceed by applying the 2016 EULAR/ACR/PRINTO criteria.\n\n**Derivation of Solution**\n\nThe $2016$ EULAR/ACR/PRINTO classification criteria for MAS in sJIA state that a febrile patient with known or suspected sJIA is classified as having MAS if the following conditions are met:\n\n1.  **Entry Criterion:** The patient must be febrile. The problem states the child has \"persistent fever\". This criterion is met.\n\n2.  **Primary Combination of Criteria:** The patient must have a serum ferritin level $> 684 \\, \\mathrm{ng/mL}$ **AND** meet at least $2$ of the following $4$ criteria:\n    - Platelet count $\\leq 181,000/\\mu \\mathrm{L}$\n    - AST $> 48 \\, \\mathrm{U/L}$\n    - Triglycerides $> 156 \\, \\mathrm{mg/dL}$\n    - Fibrinogen $\\leq 3.6 \\, \\mathrm{g/L}$\n\nWe will now systematically evaluate the patient's data against these criteria.\n\n- **Ferritin Criterion:**\n    - Patient's value: $3000 \\, \\mathrm{ng/mL}$\n    - Threshold: $> 684 \\, \\mathrm{ng/mL}$\n    - Comparison: $3000 > 684$.\n    - **Verdict: The ferritin criterion is met.**\n\n- **Additional Criteria (at least 2 required):**\n\n    1.  **Platelet Count:**\n        - Patient's value: $120,000/\\mu \\mathrm{L}$\n        - Threshold: $\\leq 181,000/\\mu \\mathrm{L}$\n        - Comparison: $120,000 \\leq 181,000$.\n        - **Verdict: The platelet criterion is met.**\n\n    2.  **AST Level:**\n        - Patient's value: $80 \\, \\mathrm{U/L}$\n        - Threshold: $> 48 \\, \\mathrm{U/L}$\n        - Comparison: $80 > 48$.\n        - **Verdict: The AST criterion is met.**\n\n    3.  **Triglycerides:**\n        - This value is not provided in the problem statement. However, since the requirement is to meet any two of the four criteria, we can proceed to evaluate the fourth criterion.\n\n    4.  **Fibrinogen Level:**\n        - Patient's value: $1.2 \\, \\mathrm{g/L}$\n        - Threshold: $\\leq 3.6 \\, \\mathrm{g/L}$\n        - Comparison: $1.2 \\leq 3.6$. The units are consistent, so no conversion is necessary.\n        - **Verdict: The fibrinogen criterion is met.**\n\n**Conclusion of Criteria Application:**\nThe patient is febrile and has sJIA. The mandatory ferritin criterion is met ($3000 \\, \\mathrm{ng/mL} > 684 \\, \\mathrm{ng/mL}$). The patient meets $3$ of the additional criteria (platelets, AST, and fibrinogen), which is more than the minimum requirement of $2$. Therefore, based on the provided clinical and laboratory data, the patient meets the 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome. The absence of a triglyceride value does not preclude this classification.\n\n**Option-by-Option Analysis**\n\n- **A. The patient meets MAS classification criteria without needing any additional laboratory values.**\nThis statement aligns perfectly with our derivation. The provided data (fever, ferritin, platelets, AST, fibrinogen) are sufficient to satisfy the 2016 EULAR/ACR/PRINTO criteria. The triglyceride level is not required.\n**Verdict: Correct.**\n\n- **B. The patient does not meet MAS classification criteria because the fibrinogen is not low after proper unit conversion.**\nThe fibrinogen threshold is $\\leq 3.6 \\, \\mathrm{g/L}$. The patient's value is $1.2 \\, \\mathrm{g/L}$. Since $1.2 \\leq 3.6$, the criterion is met. The units are already in $\\mathrm{g/L}$ and require no conversion. The premise of this option is factually incorrect.\n**Verdict: Incorrect.**\n\n- **C. The patient does not meet MAS classification criteria because the ferritin is below the required threshold for classification in sJIA.**\nThe ferritin threshold is $> 684 \\, \\mathrm{ng/mL}$. The patient's value is $3000 \\, \\mathrm{ng/mL}$. Clearly, $3000 > 684$, so the patient's ferritin is well above the required threshold. This statement is factually incorrect.\n**Verdict: Incorrect.**\n\n- **D. The patient meets MAS classification criteria only if fasting triglycerides are elevated; without triglycerides, MAS cannot be classified.**\nThis is incorrect. The criteria require any $2$ of $4$ specific laboratory abnormalities. The patient already meets $3$ of them (platelets, AST, fibrinogen) from the supplied data. Therefore, the triglyceride value is not needed to make the classification in this case.\n**Verdict: Incorrect.**\n\n- **E. The patient does not meet MAS classification criteria because the platelet count must be $\\leq 100{,}000/\\mu \\mathrm{L}$ to qualify.**\nThis statement uses an incorrect threshold for platelet count. The correct threshold in the 2016 EULAR/ACR/PRINTO criteria for MAS in sJIA is $\\leq 181,000/\\mu \\mathrm{L}$. The threshold of $\\leq 100,000/\\mu \\mathrm{L}$ is associated with different criteria sets (e.g., HLH-2004), which are not the specific established criteria for MAS in sJIA. The patient's platelet count of $120,000/\\mu \\mathrm{L}$ meets the correct threshold ($120,000 \\leq 181,000$).\n**Verdict: Incorrect.**\n\nBased on the comprehensive analysis, only option A is a correct conclusion.", "answer": "$$\\boxed{A}$$", "id": "5165130"}, {"introduction": "Effective and safe treatment is the cornerstone of JIA management, and this relies on precise pharmacotherapy. For many systemic agents in pediatrics, including the core disease-modifying drug methotrexate, dosing based on body surface area ($BSA$) is superior to weight-based dosing because it more accurately reflects metabolic rate and drug clearance. This fundamental exercise will test your ability to perform this essential calculation, ensuring patient safety and therapeutic efficacy [@problem_id:5165146].", "problem": "Juvenile Idiopathic Arthritis (JIA) commonly employs methotrexate as a weekly disease-modifying antirheumatic drug (DMARD). In pediatric pharmacotherapy, dose scaling by body surface area (BSA) relies on the principle that drug dose per unit surface area is approximately proportional to metabolic capacity and clearance across pediatric sizes, making body surface area an empirically validated surrogate for physiologic scaling. Consider a child with body surface area (BSA) equal to $0.8\\,\\mathrm{m}^{2}$. The recommended weekly methotrexate dose for JIA is $15\\,\\mathrm{mg}/\\mathrm{m}^{2}$ administered subcutaneously. Using dimensional analysis and proportionality from first principles of dose-per-area scaling, compute the absolute weekly dose in milligrams for subcutaneous administration. Express the final dose in milligrams (mg). If you choose to round, round your answer to three significant figures.", "solution": "The problem statement is first subjected to a rigorous validation process.\n\n### Step 1: Extract Givens\nThe following data are explicitly provided in the problem statement:\n- The body surface area (BSA) of the child is $A = 0.8\\,\\mathrm{m}^{2}$.\n- The recommended weekly dose concentration of methotrexate is $C = 15\\,\\mathrm{mg}/\\mathrm{m}^{2}$.\n- The task is to compute the absolute weekly dose, which we will denote as $D$, in units of milligrams ($\\mathrm{mg}$).\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated against the established criteria for validity.\n\n- **Scientifically Grounded**: The problem is firmly rooted in the principles of pharmacokinetics, a core discipline within pharmacology and medicine. The use of methotrexate for Juvenile Idiopathic Arthritis (JIA) is a standard of care. Dose scaling by body surface area (BSA) is a widely accepted and empirically validated method in pediatrics and oncology to account for metabolic rate and drug clearance differences across patients of varying sizes. The specified dose of $15\\,\\mathrm{mg}/\\mathrm{m}^{2}$ per week is a common and clinically appropriate starting dose for JIA. The patient's BSA of $0.8\\,\\mathrm{m}^{2}$ is a realistic value for a school-aged child. Therefore, the problem's premises are factually and scientifically sound.\n\n- **Well-Posed**: The problem is unambiguous and provides all necessary information to determine a unique solution. The relationship between the given quantities and the desired quantity is clearly defined by the principle of dose-per-area scaling. There are neither missing data (underspecified) nor contradictory constraints (overconstrained).\n\n- **Objective**: The problem is stated in clear, precise, and quantitative language. It is free of subjective claims, opinions, or metaphorical language.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid** as it is scientifically grounded, well-posed, objective, and directly solvable using fundamental principles of dimensional analysis and proportionality as described. The solution process may proceed.\n\n### Solution\nThe problem requires the calculation of the absolute weekly dose of methotrexate for a child, based on a recommended dose per unit of body surface area. The fundamental principle is that the total dose is directly proportional to the patient's body surface area.\n\nLet $D$ represent the absolute weekly dose in milligrams ($\\mathrm{mg}$).\nLet $A$ represent the patient's body surface area in square meters ($\\mathrm{m}^{2}$).\nLet $C$ represent the recommended dose concentration, defined as the amount of drug per unit of body surface area, in units of $\\mathrm{mg}/\\mathrm{m}^{2}$.\n\nThe relationship between these quantities is given by the direct proportionality:\n$$D = C \\times A$$\n\nFrom the validated problem statement, we have the following values:\n$$C = 15\\,\\frac{\\mathrm{mg}}{\\mathrm{m}^{2}}$$\n$$A = 0.8\\,\\mathrm{m}^{2}$$\n\nSubstituting these values into the equation for the absolute dose $D$:\n$$D = \\left( 15\\,\\frac{\\mathrm{mg}}{\\mathrm{m}^{2}} \\right) \\times (0.8\\,\\mathrm{m}^{2})$$\n\nThe dimensional analysis confirms the correctness of the approach, as the units of square meters ($\\mathrm{m}^{2}$) cancel out, leaving the desired unit of milligrams ($\\mathrm{mg}$):\n$$D = (15 \\times 0.8)\\,\\mathrm{mg}$$\n\nThe numerical calculation is performed:\n$$15 \\times 0.8 = 15 \\times \\frac{8}{10} = \\frac{120}{10} = 12$$\n\nThus, the absolute weekly dose is exactly $12\\,\\mathrm{mg}$. The problem statement includes an instruction about rounding to three significant figures, but since the calculation results in an exact integer, no rounding is necessary or appropriate.\n\nThe final computed absolute weekly dose for subcutaneous administration is $12\\,\\mathrm{mg}$.", "answer": "$$\\boxed{12}$$", "id": "5165146"}]}